The protective immunity induced by intranasally inoculated serotype 63 chimpanzee adenovirus vector expressing human respiratory syncytial virus prefusion fusion glycoprotein in BALB/c mice

Abstract

Human respiratory syncytial virus (RSV) is a ubiquitous pediatric pathogen causing serious lower respiratory tract disease worldwide. No licensed vaccine is currently available. In this work, the coding gene for mDS-Dav1, the full-length and prefusion conformation RSV fusion glycoprotein (F), was designed by introducing the stabilized prefusion F (preF) mutations from DS-Cav1 into the encoding gene of wild-type RSV (wtRSV) F protein. The recombinant adenovirus encoding mDS-Cav1, rChAd63-mDS-Cav1, was constructed based on serotype 63 chimpanzee adenovirus vector and characterized in vitro. After immunizing mice via intranasal route, the rChAd63-mDS-Cav1 induced enhanced neutralizing antibody and F-specific CD8+ T cell responses as well as good immune protection against RSV challenge with the absence of enhanced RSV disease (ERD) in BALB/c mice. The results indicate that rChAd63-mDS-Cav1 is a promising mucosal vaccine candidate against RSV infection and warrants further development.

A novel simian adenovirus vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

“…The copyright holder for this preprint (which this version posted April 19, 2023. ; https://doi.org/10.1101/2023.04.17.537220 doi: bioRxiv preprint virus (RSV) or MERS-CoV infection (35,36,37). In this study, we utilized a novel simian adenovirus 23 6).…”

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

“…Two needle-free COVID-19 vaccines that are delivered through the mouth or nose have been approved for use in China and India, which are generated with adenovirus vectors by CanSino Biologics or Bharat Biotech ( 18 ). Moreover, several studies have shown the advantage of adenovirus-vectored vaccines in eliciting mucosal immunity with protective effects against respiratory virus infections such as Ebola virus, human respiratory syncytial virus (RSV), or MERS-CoV infection ( 31 – 33 ). In this study, we utilized a novel simian adenovirus 23 vectored COVID-19 vaccine (Sad23L-nCoV-S) with low pre-existing immunity in humans to evaluate the effects of systemic and local mucosal immunity in mice by different immunization regimens via IN and IM routes.…”